

The logo for amoéba is a stylized circular emblem composed of two overlapping crescent shapes. The top-left portion is a vibrant blue, and the bottom-right portion is a bright green. The word "amoéba" is written in a clean, white, lowercase sans-serif font, centered horizontally and partially overlaid by the logo.

amoéba

ROADSHOW PRESENTATION

2023

DECEMBER 2023

DISCLAIMER

References herein to this presentation (the "Presentation") shall mean and include this document, any oral presentation accompanying this document provided by Amoeba SA (the "Company"), any question and answer session following that oral presentation and any further information that may be made available in connection with the subject matter contained herein.

This Presentation has been prepared by the Company and is for information only. This document does not purport to contain comprehensive or complete information about the Company and is qualified in its entirety by the business, financial and other information that the Company is required to publish in accordance with the rules, regulations and practices applicable to companies listed on the multilateral trading facility of Euronext Growth, including, in particular, the risk factors set out in the universal registration document (the "URD") filed with the French Financial Markets Authority (Autorité des marchés financiers) (the "AMF") on April 18, 2023 under number D.23-0296, and in any other periodic report, which are available free of charge on the websites of the Company (<https://amoeba-nature.com>) and the AMF (www.amf-france.org). Information and other data appearing in such publications, and certain figures and numbers appearing in this document have been rounded. Consequently, the total amounts and percentages appearing in tables and elsewhere may not necessarily equal the sum of the individually rounded figures, amounts or percentages.

No representation, warranty or undertaking, express or implied, is made as to the accuracy, completeness or appropriateness of the information and opinions contained in this Presentation, or its use for any purpose, and no reliance should be placed on any information or opinions contained herein. The Company, its subsidiaries, its advisors and representatives accept no responsibility for and shall not, under any circumstance, be held liable for any loss or damage that may arise from the use of this document or the information or opinions contained in it. In particular, this document contains information on the Company's markets and competitive position, and more specifically, on the size of its markets. This information has been drawn from various sources or from the Company's own estimates which may not be accurate and thus no reliance should be placed on such information. Any prospective investors must make their own investigation and assessments and consult with their own advisors concerning any evaluation of the Company and its prospects, and this document, or any part of it, may not form the basis of or be relied on in connection with any investment decision.


The information and opinions contained in this document are provided as of the date of this document only and may be updated, supplemented, revised or amended, and thus such information is subject to change at any time. Neither the Company, its subsidiaries, directors, officers, employees, agents, affiliates nor its advisors, nor any other person is under any obligation to update the information, statements or opinions contained in this Presentation. Nothing contained in this Presentation is or should be relied upon as a promise or representation as to the future.

All statements in the Presentation other than statements of historical fact are or may be deemed to be forward-looking statements. These forward-looking statements are not guarantees of future performance and involve a number of known and unknown risks and uncertainties. These risks and uncertainties, and other factors, could adversely affect the outcome of the forward looking statements, and actual results could differ materially from those contemplated in the statements. As a result, you are cautioned not to rely on such forward-looking statements. Forward-looking statements speak only as of the date of this document and the Company expressly disclaims any obligation or undertaking to update or re-issue any forward-looking statements contained in this Presentation.

This Presentation does not constitute or form any part of any offer to sell, or the solicitation of an offer to buy or subscribe for, any shares or securities in the Company, in the United States or in any other jurisdiction.

All persons accessing this document are deemed to agree and comply with all the limitations and restrictions set out above.

AMOÉBA'S VALUATION



* Functional plant / investment

AMOEBAS POSITIONING



Vines

€ 800M
(powdery and downy mildew)

Strawberry
Cucumber
Tomato

Vegetables

€ 600M

Potato

€ 250M

Rice

App. € 1000 M

Banana

App. € 500 M

Arboricultures and others

App. € 100 M

Wheat

€ 2 400M

Soybeans

€ 2 100M

Global Market Volume : € 7 750 Mds

Main target

Secondary target

BIOCIDE, A VALUABLE ASSET OF AMOEBA



The first biological biocide **approved** for industrial water treatment

- A **patented innovation** in a sector that has been stagnant for 50 years
- **December 2022 : Approval from US EPA** for use in closed cooling systems in the USA.



\$ 200 M

Per year of achievable market potential in the US
Immediate addressable market.

\$ 10 M

Of construction costs for the plant in the USA



High profitability on sales due to remarkable industrial efficiency



Possible assistance of Amoéba in the industrial and commercial project

PROJECTION 2024



To guarantee the emergence of a **future French world leader** in biocontrol



Contribute to the creation of a **biocontrol industrial network** in France

Thanks to our vision and mission



Ensuring a **sustainable future** by offering biological alternatives that respect human health and the environment



Develop a **scientific and industrial** expertise to contribute to expand the offer of eco-friendly products



Demonstrate our **relevance and positive influence** in targeted sectors by 2024



Leading the way for other alternatives to chemical treatment of key resources




AMOEBIA PRESENTATION




ABOUT AMOEBA



Amoéba is an industrial biotech in pre-commercialization that provides microbiological solutions for the treatment of natural key resources.



WILLAERTIA MAGNA C2C MAKY
One microorganism, several applications



Scientific maturity

10 years of R&D

9 scientific publications




Regulatory maturity

Europe : Recommendation for approval by Austria announced in **April 2022**

USA : US EPA approval of biocontrol solution in **November 2022**

AMOEBBA KEY FIGURES



25

Millions of euros invested in R&D since 2010



28

Employees in France



1

Industrial expertise centre dedicated to industrial research and development



GOVERNANCE



Benoit Villers

President

*Managing Director &
Board Member at Nice & Green*



Fabrice Plasson

Founder and Administrator

Expert in life science and biologies



Valérie Filiatre

Administrator

*Expert in business administration
and finance*



Jean-Luc Souche

Administrator

Specialist in plant protection



Pierre Morgon

Administrator

Expert in life and health science



Sylvie Guinard

Administrator

Expert in industrial processes



Philippe Dujardin

Administrator

Expert in finance and strategy

BOARD OF DIRECTORS



Jean-François Doucet

General Deputy
Expert in finance



Jean-Baptiste Eberst

Regulatory affairs Director
Expert in regulatory affairs



Sandrine Troussieux

Scientific Director
*Dr. in Sciences, specialized in
environmental microbiology*



Hervé Testeil

Industrial Director
*Industrial expert in pharmaceuticals,
medical devices and biotechnologies*



2

FINANCIAL INFORMATION

FINANCING AND SHAREHOLDING



€ 13.2 M

Raised during the IPO in July 2015

€ 14.7 M

Raised in 2016 by private placement

€ 5 M

Financing agreement with the European Investment Bank (EIB) in 2017

€ 32 M

OCAPI with Nice & Green between 2018 and 2022


€ 6 M

Other funds raised, subsidies, refundable advances and loans

€ 70,9 M

Invested in the Company since its creation

Distribution of shareholding



- Individual shareholders
- CEO and historical shareholders

FINANCIAL SITUATION



BURN RATE

2021

€ 370 K

2022

€ 390 K

EIB DEBT

Refunded in June 2022

2021

€ 6,1 M

2022

€ 0 M

EQUITY

2021

€ 0,2 M

2022

€ 8,2 M

CASHFLOW

2021

€ 7,3 M

2022

€ 5,5 M



3

BIOCONTROL


CURRENT ISSUES

78% reduction of insects between 1989 and 2013 : **impact on biodiversity**


46% of the foodstuffs analyzed by EFSA are contaminated by pesticide residues : **impact on public health**

Strong **environmental impacts** : soil and air pollution

European objectives towards biocontrol



25% Organic farming crops in Europe by 2030



50% Reduction of plant protection products of greatest concern in Europe by 2030. Copper re-evaluation in 2026



60% of uses covered by biocontrol products in 2025

AXPERA

Amoéba's expertise at the service of a new era
in plant protection



Why AXPERA ?

- Expert / **Expertise**
- **Era** (new era in plant protection through effective and safe biocontrol)
- **AXP**: reminder of our experimental formulations (AXP12, AXP13, AXP17)
- Values of **innovation, performance, responsibility and renewal**

AXPERA **JOY**

AXPERA **EVA**

AXPERA **NOA**

OUR SOLUTION



2022 (FR) – Untreated (downy mildew)




2022 (FR) – Amoéba treatment (downy mildew)

A 100% natural biofungicide

90%

Effectiveness in climatic chambers on mildew and rusts



50 à 95%

Effectiveness in field



[Read more about Amoeba](#)

300

Trials by Amoéba since 2019

180


Trials by partners since 2019

+15

Countries around 4 continents



Facilitating the transition from conventional to organic agriculture



Thanks to our solution :

- A **unique dual mode of action** (elicitor and fungicide)
- A **wide spectrum** of activity (vineyards, vegetables, potatoes, cereals...)
- A **good complementary with conventional** products

KEY FACTORS OF SUCCESS



An **innovative and unique product** from a class of microorganisms never used before in agriculture: **amoebas**



An active substance **recommended for approval** by the Rapporteur Member State (Austria) and **approved** by US EPA



A product with **no hazard class** and a **low risk profile**



A product with a **high level of performance**, often unmatched for a biocontrol product, that guarantees **yield gains**



A product with **no maximum residue limit**



A product with an established technical reputation: **Innovation Award** received at the Plant BioProTech Congress in Reims (June 2022).



A product with no **pre-harvest delay**



4

INDUSTRIALIZATION

INDUSTRIALIZATION



Chassieu Industrial R&D Center

2 x 500 L

Production capacity of
bioreactors

500 KG

of active substance
produced per year

PRODUCTION SITE EXPANSION PROJECT



Creation of a new duplicable factory in Cavailon Biocontrol production line

23 M €

Of investments

3000 m²

surface area, including 2000m² entirely dedicated to production

40 T

of additional active substance, **up to 80 T** in case of extension

100 000 ha

hectares treated, **up to 200,000 hectares** in case of extension

2023

2024

2025

APD

BP

Instruction

Construction

Qualif.

Go Live

Commercial production

A SITE WITH THE PARC+ LABEL



A responsible industrial approach at the heart of a dedicated park

- Business park dedicated to **naturalness**
- **Preservation and enhancement** of the landscape, natural resources and local quality of life
- Installation of **photovoltaic panels** on 60% of the roofs
- Recycling of **industrial water**
- **Geothermal** energy
- Use of **bio-sourced** materials
- Preservation of the biotope (fauna / flora)

Plant of Future Model: Artificial Intelligence and Eco-Responsibility

AN OPTIMISATION PROJECT IN SEVERAL PHASES



NOE – Chassieu (*Existing line*)

Bioreactors : 2 x 500 L

5 années of maturity of process developments

500 KG of active substance produced per year



NOE – Chassieu

Bioreactor : 1600L / day

Scale-up of a pilot line at Chassieu :

- To optimize process control
- To develop industrial excellence models
- To launch the USIBIAM project in the best conditions



USIBIAM – Cavillon (*Production line*)

Bioréacteurs : 4 x 5000 L

A.I 4.0

- Integration of optimised formulation and packaging operations
- Centralised control centre dedicated to the autonomous production unit.
- Full MES / SPC.
- Automation of operations



AMOEBBA'S STRATEGY 2024-2026



A volume and profitability strategy

40 tons of AS/year
=
100 000 hectares treated



Vines
(2 771 000 hectares)



Lettuce
(500 000 hectares)



Tomato
(280 000 hectares)



Aromatic herbs
(30 000 hectares)

Price/ha
50 €

Price/ha
100 €

Price/ha
100 €

Price/ha
250 €



AXPERA EVA



AXPERA NOA




AXPERA NOA



AXPERA JOY



AMOEBBA'S PROJECT FINANCING



€ 45 M

required for the realization of the project

€ 23 M

Dedicated to the factory construction

€ 22 M

Dedicated to operating expenses over 2023 - 2024

FINANCING PLAN

Finding a balance between equity and banking

€ 9 M by Nice & Green

€ 5,9 M by BPI FRANCE



NICE & GREEN
Leading Swiss Funding Firm

bpifrance



suitable for Socially Responsible Investment (SRI)

The logo for 'amoéba' features the word in a white, lowercase, sans-serif font. It is partially enclosed by a circular graphic composed of two overlapping crescent shapes: a blue one on top and a green one on the bottom. A thin white horizontal line passes behind the text.

amoéba



Social Media
@AmoebaNature



Website
amoeba-nature.com



Contact
contact@amoeba-nature.com

DECEMBER 2023